NASH



NASH Recent News

Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment
Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients
Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist
Analyst Reactions on NGM Biopharmaceuticals Disappointing Aldafermin Data in NASH Study
Boehringer Ingelheim to Develop NASH Candidate Based On Dicerna's GalXC Platform
NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study
NGM Biopharma to Release Mid-Stage NASH Data Monday: What to Expect?
Corcept Stops Phase 2 NASH Study With Miricorilant Due To Elevated Liver Enzymes In Patients
Exclusive: Axcella Health Aims To Become The Standard Of Care
89bio's NASH Candidate Shows Clinically Meaningful Outcomes At ENDO Conference
IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week
IPO Outlook For The Week: Snowflake and Amwell Lead Busy 12 IPO Lineup
Why Shares Of NASH Biotech Intercept Pharma Are Slumping
Diverging NASH Stories: CymaBay On Track To Restart, GenFit's Drug Flunks Late-Stage Study
NGM Biopharma Shares Spike Higher On Positive NASH Study Results
13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention
ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study
Gilead Reiterates Faith In NASH Combination Approach After Another Trial Disappointment
Conatus Shares Fall By More Than 50% After Midstage Study Shows NASH Candidate Lagged Placebo
Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial
Analyst: Intercept's NASH Drug Could Launch Sans Competition After Gilead Trial Failure
Lipocine's NASH Candidate Shows Promise In Liver Fat Study